Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
      QxMD      Google Scholar   
Citation:
Blood Adv vol 2 (14) 1705-18
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
SDC:
No
Book Volume:
7
Parents:
2681  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
Leuk Corr Sci    
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA025224, U10CA180790, U10CA180820; CCTG: NCTN CA180863 and CCSRI 704970; ECOG-ACRIN: U10CA180791, U10CA180799, and U10CA180802; SWOG: U10CA180888 and U10CA180828; R03 CA186183-02  
Corr. Author:
 
Authors:
                                   
Networks:
ADM402, ADM403, ALLIANCE, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007, LAPS-WI020, OR054, PCRC   
Study
CALGB-10404
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: